Knoxville GLP-1 Weight Loss FAQ

Two: semaglutide (GLP-1 agonist; Ozempic, Wegovy) and tirzepatide (dual GIP/GLP-1 agonist; Mounjaro, Zepbound). Selection between them is clinical, based on goal, tolerance, budget, and comorbidities.

Semaglutide initiates at 0.25 mg weekly, tirzepatide at 2.5 mg weekly, with gradual escalation as tolerated. Rapid escalation drives the GI adverse events that cause discontinuation, so titration is paced and managed at monthly review.

Generally BMI ≥30, or ≥27 with a weight-related comorbidity such as dysglycemia, hypertension, or sleep apnea, in an adult with a documented weight-regain history. No fixed pound minimum, but a genuine indication is required and confirmed before initiation.

Labs (e.g., metabolic panel; A1c and lipids per case) at baseline and interval when clinically indicated, plus monthly physician review where the dose is adjusted against response and tolerance. Continuity of clinician across reviews is an adherence factor.

Approximately 15-20% of body weight by month six in many patients — contingent on dose escalation toward an effective level rather than remaining on the initiation dose. The trajectory is non-linear and plateaus are expected.

Absolute: pregnancy, lactation, personal/family history of medullary thyroid carcinoma or MEN-2. Relative: active pancreatitis, significant biliary disease, severe GI disorders, specific drug interactions. Minimal indication or eating-disorder history redirects to alternative management.